Cutaneous Oncology in the Immunosuppressed

Leo L Wang; Stephanie K Lin; Carolyn M Stull; Thuzar M Shin; H William Higgins; Cerrene N Giordano; Stacy L McMurray; Jeremy R Etzkorn; Christopher J Miller; Joanna L Walker

doi:10.1016/j.det.2022.07.012

Cutaneous Oncology in the Immunosuppressed

Dermatol Clin. 2023 Jan;41(1):141-162. doi: 10.1016/j.det.2022.07.012.

Affiliations

¹ Department of Dermatology, Perelman Center for Advanced Medicine, University of Pennsylvania, 1st Floor South Pavilion, 3400 Civic Center Boulevard, Philadelphia, PA 19104, USA.
² Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, 500 Hofstra Boulevard, Hempstead, NY 11549, USA.
³ Department of Dermatology, Perelman Center for Advanced Medicine, University of Pennsylvania, 1st Floor South Pavilion, 3400 Civic Center Boulevard, Philadelphia, PA 19104, USA. Electronic address: joanna.walker@pennmedicine.upenn.edu.

PMID: 36410975
DOI: 10.1016/j.det.2022.07.012

Abstract

Patients with immunosuppressive conditions experience an increased frequency and severity of cutaneous malignancies. This article highlights management of keratinocyte carcinoma, melanoma, Merkel cell carcinoma, and Kaposi sarcoma in the setting of lymphoproliferative disorders, acquired immunodeficiencies, and organ transplantation. Advances in the safety of organ transplant recipient immunosuppression, early identification of risk factors, and new targeted therapies are improving skin cancer outcomes in immunocompromised populations.

Keywords: Chronic lymphocytic leukemia; HIV; Immunosuppression; Kaposi sarcoma; Keratinocyte carcinoma; Melanoma; Merkel cell carcinoma; Organ transplant recipients.

Publication types

Review

MeSH terms

Carcinoma, Merkel Cell* / therapy
Humans
Immunocompromised Host
Immunosuppression Therapy / adverse effects
Skin / pathology
Skin Neoplasms* / pathology